Plus, news about Boston Oncology, Garda and Assertio, an Everest deal and Forte’s raise:

🟢 FDA ends partial hold on MacroGenics cancer drug: In February, the agency stopped a Phase 2 trial of lorigerlimab after …

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844